Bioinformatics for Precision Medicine in Oncology: principles and application to the SHIVA clinical trial

• Main Authors: Nicolas eServant, Julien eRoméjon, Pierre eGestraud, Philippe eLa Rosa, Georges eLucotte, Séverine eLair, Virginie eBernard, Bruno eZeitouni, Fanny eCoffin, Gérôme eJules-Clément, Florent eYvon, Alban eLermine, Patrick ePoullet, Stéphane eLiva, Stuart ePook, Tatiana ePopova, Camille eBarette, François ePrud'homme, Jean-Gabriel eDick, Maud eKamal, Christophe eLe Tourneau, Emmanuel eBarillot, Philippe eHupé
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2014-05-01
• Series: Frontiers in Genetics
• Subjects: bioinformatics; Sequencing; Clinical Trial; oncology; SHIVA; precision medicine
• Online Access: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00152/full

Precision medicine (PM) requires the delivery of individually adapted medical care based on the genetic characteristics of each patient and his/her tumor. The last decade witnessed the development of high-throughput technologies such as microarrays and next-generation sequencing which paved the way to PM in the field of oncology. While the cost of these technologies decreases, we are facing an exponential increase in the amount of data produced. Our ability to use this information in daily practice relies strongly on the availability of an efficient bioinformatics system that assists in the translation of knowledge from the bench towards molecular targeting and diagnosis. Clinical trials and routine diagnoses constitute different approaches, both requiring a strong bioinformatics environment capable of i) warranting the integration and the traceability of data, ii) ensuring the correct processing and analyses of genomic data and iii) applying well-defined and reproducible procedures for workflow management and decision-making. To address the issues, a seamless information system was developed at Institut Curie which facilitates the data integration and tracks in real-time the processing of individual samples. Moreover, computational pipelines were developed to identify reliably genomic alterations and mutations from the molecular profiles of each patient. After a rigorous quality control, a meaningful report is delivered to the clinicians and biologists for the therapeutic decision. The complete bioinformatics environment and the key points of its implementation are presented in the context of the SHIVA clinical trial, a multicentric randomized phase II trial comparing targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer. The numerous challenges faced in practice during the setting up and the conduct of this trial are discussed as an illustration of PM application.